All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Pulmonary hypertension (PH) is a serious condition that can present with right ventricular dysfunction, fatigue, dyspnea, syncope, chest pain, palpitations, and lower extremity edema. It is defined as a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg when diagnosed by right heart catheterization (RHC), or > 35 mmHg when diagnosed by trans-thoracic echocardiography (TTE). The frequency of PH has been shown to be elevated in patients with Philadelphia-chromosome negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), and the prognosis for these patients is fairly poor, with a median survival of ~ 2.8 years.1
Prevalence estimates of PH in patients with MPN vary between studies from < 4% to > 50%. Many confounding factors could contribute to this variance, such as the criteria for patient selection, the diagnostic tool used, MPN subtype, duration of MPN, and age. Therefore, our MPN Hub Steering Committee member, Tiziano Barbui, and colleagues carried out a systematic review and meta-analysis to estimate prevalence and predict risk factors for PH in patients with MPN. The results were recently published in the European Journal of Haematology and are summarized below. 1
Figure 1. Screening process for study inclusion1
Table 1. Characteristics of included studies1
PH, pulmonary hypertension; RHC, right heart catheterization; TTE, trans-thoracic electrocardiogram; unspec, unspecified. |
|||||||
Publication |
Study type |
Diagnosis method |
N |
n, PH |
Prevalence of PH, % |
Median age at diagnosis of PH |
Median disease duration, years |
---|---|---|---|---|---|---|---|
Garcia-Manero et al. 1999 |
Case series |
TTE |
6 |
6 |
– |
58.2 |
5.2 |
Dingli et al. 2001 |
Retrospective (Descriptive) |
RHC/ unspec. |
25 |
25 |
– |
74.0 |
8.0 |
Guilpain et al. 2008 |
Case series |
RHC/ unspec. |
10 |
10 |
– |
– |
13.5 |
Tabarroki et al. 2014 |
Prospective cohort |
TTE |
15 |
155 |
– |
– |
5.6 |
Kadikoylu et al. 2004 |
Prospective cohort |
TTE |
28 |
4 |
14.3 |
67.3 |
3.1 |
Gupta et al. 2006 |
Prospective cohort |
TTE |
23 |
12 |
52.2 |
54.5 |
6.0 |
Altintas et al. 2007 |
Prospective cohort |
TTE |
46 |
22 |
47.8 |
45.0 |
2.9 |
Cortelezzi et al. 2008 |
Case control |
TTE |
36 |
13 |
36.1 |
– |
3.3 |
Burgstaller et al. 2013 |
Case series |
RHC/ unspec. |
22 |
1 |
4.5 |
– |
– |
Mattar et al. 2016 |
Retrospective cohort |
TTE |
60 |
7 |
11.7 |
– |
– |
Austin et al. 2019 |
Retrospective cohort |
TTE |
25 |
14 |
56.0 |
70.5 |
2.5 |
Garypidou et al. 2004 |
Retrospective cohort |
TTE |
22 |
9 |
40.9 |
63.8 |
4.7 |
Chebrek et al. 2014 |
Retrospective cohort |
TTE |
71 |
3 |
4.2 |
80.0 |
1.3 |
Kim et al. 2019 |
Retrospective cohort |
TTE |
180 |
105 |
58.3 |
71.9 |
6.6 |
Brabrand et al. 2019 |
Retrospective cohort |
RHC/ unspec. |
158 |
6 |
3.8 |
70.5 |
4.0 |
Gupta et al. 2019 |
Retrospective cohort |
TTE |
65 |
37 |
56.9 |
65.0 |
2.3 |
Lopez-Mattei et al. 2020 |
Retrospective cohort |
TTE |
143 |
20 |
14.0 |
73.5 |
3.6 |
The prevalence of PH among patients with MPN varies considerably between published studies. Factors that influence this heterogeneity were found to be the method of diagnosis of PH, median patient age, the proportion of patients with MF, and duration of disease. The risk of PH was demonstrated to be highest for patients with MF, particularly those with PMF, and lowest in patients with PV, suggesting there are important biological differences between these types of MPN.
Limitations of this study include the small cohort size of the included studies, and that the only study that prospectively defined criteria for RHC also had the lowest prevalence of PH, so could be largely responsible for the variance observed between the PH prevalence and diagnostic modalities.
To better understand the prevalence of PH in patients with MPN and its impact on morbidity and survival, future prospective trials are required and should include cross-sectional data sets representative of patients of different ages, MPN diagnoses, and duration of MPN. They should also include patient reported symptoms, objective cardiovascular function assessments, and a hierarchical diagnostic algorithm that prospectively defines which patients should undergo non-invasive and/or invasive testing to evaluate PH and its pathophysiology.
Subscribe to get the best content related to MPN delivered to your inbox